Orexo Confirms Meda Launch Of Edluar In The US
Meda acquired commercialization rights for Edluar from Orexo in 2008
Orexo has confirmed that Meda has initiated the launch of the drug Edluar in the US. The launch follows the US Food and Drug Administration’s approval in March this year of Edluar 5mg and 10mg sublingual tablets for the short-term treatment of insomnia characterized by difficulties with sleep initiation.
The company said that Meda acquired exclusive worldwide commercialization rights for Edluar from Orexo in 2008. Orexo will receive royalty payments on Meda’s sales of Edluar in the US.
Torbjorn Bjerke, CEO of Orexo, said: “Edluar offers insomnia sufferers a convenient and effective treatment and Meda is well placed to sell Edluar in the US market.”
Reportedly, Edluar is a fast-acting, sublingual formulation of zolpidem. It is based on Orexo’s sublingual technology, involving a tablet placed under the tongue for fast and effective absorption of the active ingredient across the oral mucosa.
Related Insight
Suppliers Directory
Laboratoria Smeets - Blending and Packaging of Pharmaceutical Powders
Laboratoria Smeets N.V. is a pharmaceutical contract manufacturing company, specialising in blending and packaging of pharmaceutical powders.
Suppliers
Biocair - Specialist Courier Services for the Biotechnology, Pharmaceutical and Scientific Research Industries
Since 1987 Biocair has built an unrivalled reputation for service quality, care, depth of knowledge and expertise spanning the four key areas of Compliance, Dangerous Goods (classification, handling and shipment), pro-active Temperature Management and Logistics; relating to the movement of research material, clinical samples and finished product.
Suppliers
Pharmatest Services - Preclinical Contract Research
Pharmatest Services Ltd is a full-service bone biology CRO specialised in preclinical testing of new drug candidates both in vitro and in vivo. We provide cost-effective solutions for fast and high quality preclinical drug efficacy research.
Suppliers
Accuri Cytometers - Flow Cytometry
Accuri Cytometers, Inc. was founded to address a compelling need: life scientists love the rapid analysis capability of flow cytometers, but too few have a flow cytometer in their lab.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Intelligent Packaging: The Ultimate in Temperature Control
Published by SCA Cool Logistics
White Papers
Go Digital or Die
Published by NNIT
White Papers
Auto Injectors: From Planning to Launch
Published by SHL Group (Scandinavian Health Group Ltd.)
White Papers
Ideas About the Future of the Innovative Pharmaceutical Industry
Published by Kinapse
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.